Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington’s Disease: Are They Fit-for-Purpose for Treatment Development?

A major focus in development of novel therapies for Huntington’s disease (HD) is identification of treatments that reduce the burden of mutant huntingtin (mHTT) protein in the brain. In order to identify and test the efficacy of such therapies, it is essential to have biomarkers that are sensitive t...

Descripción completa

Detalles Bibliográficos
Autores principales: Leuchter, Michael K., Donzis, Elissa J., Cepeda, Carlos, Hunter, Aimee M., Estrada-Sánchez, Ana María, Cook, Ian A., Levine, Michael S., Leuchter, Andrew F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371600/
https://www.ncbi.nlm.nih.gov/pubmed/28424652
http://dx.doi.org/10.3389/fneur.2017.00091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371600/
https://www.ncbi.nlm.nih.gov/pubmed/28424652
http://dx.doi.org/10.3389/fneur.2017.00091

Ejemplares similares